Skip to main content

buprenorphine/naloxone (Suboxone®)

 

Following a limited submission

AWMSG advice

Status: Recommended with restrictions

Buprenorphine/naloxone (Suboxone®) sublingual film is recommended as an option for restricted use within NHS Wales as substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment.  The intention of the naloxone component is to deter intravenous misuse. Suboxone® is indicated in adults and adolescents over 15 years of age who have agreed to be treated for addiction.  In accordance with NICE guidance such treatment should be considered in patients who are unsuitable for maintenance treatment with methadone.

 Final Recommendation: buprenorphine naloxone (Suboxone) 4590 (PDF, 305Kb)
 Appraisal Report: buprenorphine naloxone (Suboxone) 4590 (PDF, 81Kb)

Medicine details

Medicine name buprenorphine/naloxone (Suboxone®)
Formulation 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, 12 mg/3 mg sublingual film
Reference number 4590
Indication

Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Suboxone is indicated in adults and adolescents over 15 years of age who have agreed to be treated for addiction

Company Indivior UK Ltd
BNF chapter Central nervous system
Submission type Limited
Status Recommended with restrictions
Advice number 0621
NMG meeting date 03/03/2021
AWMSG meeting date 20/04/2021
Date of issue 28/04/2021